About This Reference Desk

What Freebase Peptides is

Freebase Peptides is an independent editorial reference desk covering the published research on three peptides studied for metabolic regulation and weight management: retatrutide, MOTS-c, and tesamorelin, with retatrutide as the lead. The site exists to make a scattered and frequently overstated literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species, and how far that evidence reaches.

The organizing frame is metabolic mechanisms: three compounds that each engage metabolism from a different structural level — receptor-driven incretin pharmacology (retatrutide), mitochondrial energy sensing (MOTS-c), and pituitary axis modulation (tesamorelin). Reading all three together gives a more complete view of the metabolic research landscape than any one alone. Each compound has its own page; a comparison page lines them up side by side; and a single shared references list aggregates every source.

How it is compiled

Three principles govern what appears on this site.

First, everything is anchored to the peer-reviewed literature. Every research claim is tied to a numbered citation — PubMed-indexed journal articles and reviews, with DOIs or PubMed/PMC links — collected on the references page. Where a finding comes from a review rather than a primary study, the review is cited as such.

Second, the evidence is reported at its actual strength. Approval status is stated plainly: tesamorelin is FDA-approved for a specific and narrow indication; retatrutide is in Phase 3 trials; MOTS-c has no human efficacy trials. Doses are described as they were studied — for example, "12 mg subcutaneously once weekly in a Phase 2 obesity RCT" — never extrapolated or framed as a recommendation. Where evidence is from animals, or from a single study, or limited to a specific population, the page says so.

Third, the three pages are cross-referenced. Because the same metabolic themes — insulin sensitivity, visceral fat, energy expenditure, GH axis — recur across compounds, the pages link to one another so a reader can follow a mechanism from one peptide to the next.

What it is not

Freebase Peptides is not a store, not a clinic, and not a source of medical advice. It does not sell, supply, source, or broker any peptide or research chemical, and it has no affiliate or referral relationship with any vendor. It does not employ clinicians, diagnose conditions, or prescribe anything. It does not recommend a dose, schedule, or route of administration for any person.

The compounds discussed here range from an FDA-approved prescription drug for a specific indication (tesamorelin) to an investigational Phase 3 compound (retatrutide) to a research chemical with no approved human use (MOTS-c). That difference matters: reading about a compound here is not the same as having access to clinical-grade material, clinical oversight, or a therapeutic indication. Readers seeking guidance about a metabolic condition should consult a licensed clinician operating within their jurisdiction, using regulated, evidence-based options.